Legend Biotech
Legend Biotech is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Legend Biotech.
Legend Biotech is a company.
Key people at Legend Biotech.
Legend Biotech is a global, commercial-stage biotechnology company specializing in the discovery, development, manufacturing, and commercialization of novel cell therapies, primarily CAR-T therapies for oncology.[1][2][3] It focuses on treating hematologic malignancies like multiple myeloma and expanding into solid tumors, serving patients with intractable diseases through innovative platforms including CAR-T, CAR-NK, CAR-γδ T, and non-gene-editing CAR technologies.[2][3][4] The company solves unmet needs in cancer treatment by advancing therapies like CARVYKTI® (ciltacabtagene autoleucel, co-developed with Janssen), with strong growth shown in recent data presentations at ASH 2025, new facility openings, and global expansions as of late 2025.[3]
Its mission is to transform lives through innovative cell therapies, pursuing cures for life-threatening diseases, while its vision positions it as a global leader in cell and gene therapy.[1][4][5]
Legend Biotech was founded in 2014 as an early-stage cell therapy company by visionary scientists with expertise in immunology and gene editing, initially operating as the "Legend Project" in a small space targeting multiple myeloma therapies.[2][6] The idea emerged from recognizing the potential of antibody-based therapeutics, leading to breakthroughs like producing nanobodies and pioneering CAR-T cells targeting the BCMA protein—one of the first worldwide—in 2015.[2]
Pivotal moments included investigator-initiated trials in China in 2016, data presentations at ASCO in 2017 that secured a key partnership with Janssen Biotech for co-developing cilta-cel, and evolution into a fully integrated, global commercial-stage company by 2025 with expanded pipelines and manufacturing.[2][3]
Legend Biotech rides the explosive growth in cell and gene therapy, a trend accelerated by successes in CAR-T for blood cancers amid rising cancer incidence and demand for personalized medicine.[1][3] Timing is ideal post-2020s regulatory approvals for CAR-T therapies, with market forces like aging populations, refractory cancer challenges, and investments in biotech manufacturing favoring its global footprint across the US, China, and Europe.[2][4][6]
It influences the ecosystem by co-developing standards like CARVYKTI®, expanding access via new facilities and approvals, and pioneering next-gen platforms that could cure solid tumors, shaping competition and investor interest in oncology biotech.[3][4]
Legend Biotech is poised for accelerated growth through pipeline advancements, with 9 ASH 2025 presentations signaling robust data in multiple myeloma and novel platforms, plus expansions like its Philadelphia facility and J.P. Morgan Healthcare Conference presence in December 2025.[3] Trends like AI-driven therapy design, global manufacturing scale-up, and combination therapies will propel it toward broader indications in solid tumors and autoimmune diseases.
Its influence may evolve from CAR-T pioneer to diversified cell therapy leader, potentially dominating intractable disease markets if manufacturing and access hurdles are cleared—reinforcing its mission to deliver hope through curative innovations.[1][2][4]
Key people at Legend Biotech.
